Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

ClinicalTrials.gov ID: NCT00484419

Public ClinicalTrials.gov record NCT00484419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effects of Colesevelam HCl, Avandia® (Rosiglitazone Maleate), or JanuviaTM (Sitagliptin) on Glycemic Parameters and Lipid Profiles in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A 16 week open-label study with subjects receiving background metformin monotherapy. 150 subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open label rosiglitazone, or open-label sitagliptin.

Study identification

NCT ID
NCT00484419
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Daiichi Sankyo
Industry
Enrollment
169 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2007 (Type not available)
Primary completion
Apr 2008 (Actual)
Completion
Apr 2008 (Actual)
Last update posted
Oct 4, 2016

2007 – 2008

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Not listed La Mesa California — —
Not listed Los Angeles California — —
Not listed Los Gatos California — —
Not listed San Antonio California — —
Not listed Chiefland Florida — —
Not listed Gary Indiana — —
Not listed Baltimore Maryland — —
Not listed Dearborn Michigan — —
Not listed West Bloomfield Michigan — —
Not listed Las Vegas Nevada — —
Not listed Yonkers New York — —
Not listed Lexington North Carolina — —
Not listed Winston-Salem North Carolina — —
Not listed Munroe Falls Ohio — —
Not listed Zaneville Ohio — —
Not listed Portland Oregon — —
Not listed Jersey Shore Pennsylvania — —
Not listed Clemson South Carolina — —
Not listed Harriman Tennessee — —
Not listed Dallas Texas — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00484419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 4, 2016 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00484419 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →